Compare · DXCM vs HRC
DXCM vs HRC
Side-by-side comparison of DexCom Inc. (DXCM) and Hill-Rom Holdings Inc (HRC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and HRC operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 2.7x HRC ($10.27B).
- DXCM has hit the wire 6 times in the past 4 weeks while HRC has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 6 for HRC).
- Company
- DexCom Inc.
- Hill-Rom Holdings Inc
- Price
- $71.54+1.52%
- $155.94+0.02%
- Market cap
- $27.61B
- $10.27B
- 1M return
- +2.57%
- -
- 1Y return
- -20.08%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- n/a
- News (4w)
- 6
- 0
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Hill-Rom Holdings Inc
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates through Patient Support Systems, Front Line Care, and Surgical Solutions segments. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, patient mobility solutions, non-invasive therapeutic products and surfaces, and information technologies and software solutions, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as patient exam and diagnostics, patient monitoring, diagnostic cardiology, vision screening, and diagnostics products; and respiratory health products comprising non-invasive devices that provide respiratory support and assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include tables, lights, and pendants; and positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables. It sells and rents products to acute and extended care facilities through direct sales force and distributors; sells and rents products directly to patients in the home; and sells products to primary care facilities through distributors. Hill-Rom Holdings, Inc. was founded in 1915 and is headquartered in Chicago, Illinois.
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
Latest HRC
- SEC Form 15-12B filed by Hill-Rom Holdings Inc
- SEC Form 10-K/A filed by Hill-Rom Holdings Inc (Amendment)
- SEC Form 4: Groetelaars John P returned 34,870 shares to the company, closing all direct ownership in the company
- SEC Form 4: Frank Andreas G returned 16,539 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Enxing Seng Stacy
- SEC Form 4: Giertz James R returned 2,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Dempsey William G returned 5,376 shares to the company, closing all direct ownership in the company
- SEC Form 4: Ladone Mary Kay returned 2,284 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Ellis Gary Lee
- SEC Form 4 filed by Schlichting Nancy M